Full Press Release Details
Creative Medical Technology Holdings, Inc. December 2018 Shareholder
PHOENIX, Dec. 27, 2018 /PRNewswire/ -- (OTCQB-CELZ)
Creative Medical Technology Holdings, Inc. announced today an update of its activities:
As we end 2018 we look forward to continuing to reach multiple
CaverStem domestic activities: As previously
reported, we are continuing marketing to physicians across the United States. Additional physicians are scheduled for training,
patients are being treated and revenues are being generated and increasing each month.
We anticipate reaching financial self-sufficiency by revenues
Physician Marketing Campaigns: Scheduled for release in January
2019, CaverStem will begin a series of mailer and email campaigns introducing the CaverStem procedure
to licensed physicians in the areas of urology, sexual function and plastic surgery. This campaign which will be expanded on a
monthly basis with follow up mailers and emails and calls from our sales representatives. It's our goal to reach out to a minimum
of 2500 new physicians each month by these methods.
Brand Awareness to Patients: Scheduled for launch in January
2019, CaverStem will increase its online presence on Social Media by sponsorships and banner advertising on websites
and search engines attracting the active male. We are currently negotiating an advertising campaign in Los Angeles as
our first city to expand into print and radio advertising.
CaverStem International: As was announced
by publication across social media outlets and our press conference, the company successfully sponsored the treatment of two patients
in Moscow using the CaverStem procedure. Treatment of patients is ongoing with positive results and is anticipated
to steadily increase in 2019. Physicians in Switzerland and Italy are being scheduled for training and patients
are being recruited.
CaverStem clinical trial: We understand the
eagerness to receive published data. We are continuing to work towards this goal of publication of the results as soon as possible.
FemCelz : as previously announced, we are
progressing with the development of the FemCelz procedure for the treatment of female sexual
dysfunction using stem cells from the patient's own bone marrow. We are preparing the patient protocol and designing the
website in anticipation of this launch in Q1. Many of our existing CaverStem affiliated physician's also
treat female patients for sexual function and we anticipate that they will be the leaders in progressing the
U.S. and international agreements have been reached for exclusive
distribution rights for the FDA approved Generation 2 bone marrow harvest technology which has been used with multiple ED patients
in the past 90 days with excellent results. By replacing the centrifuge technology with our Generation 2 technology we realize
the following benefits;
StemSpine : In order to concentrate our efforts
on CaverStem domestic and international and FemCelz , StemSpine is expected to
launch in late 2019. We feel it is in the best interest of the company to dedicate much of our resources to continue to build those
brands and our cash flow before commercializing StemSpine.
AmnioStem : We are continuing to accumulate data
in order to file for an FDA IND on the use of our amniotic stem cell for the treatment of stroke. We will advise milestones in
Other patent pending technologies: We continue to prosecute
our patent applications with the USPTO.
Acquisitions in 2019: We anticipate acquiring the Virility Centers
of America brand from affiliate company Creative Medical Health, Inc. in Q1 2019. The use of the Virility Centers brand is related
to male and female wellness clinics, including sexual function (CaverStem and FemCelz ), incontinence
and infertility. This brand will complement the CaverStem and FemCelz brands. The benefit
to the company will be
We wish everyone a Happy New Year and the CELZ team will continue
to do our best to build the fundamentals of the company, which we believe are stronger than ever.
About Creative Medical Technology Holdings
Creative Medical Technology Holdings, Inc. is a commercial stage
biotechnology company currently trading on the OTCQB under the ticker symbol CELZ. For further information about the company go
to www.creativemedicaltechnology.com. For more information on
our CaverStem procedure please go to www.caverstem.com.
Forward-Looking Statements
OTC Markets has not reviewed and does not accept responsibility
for the adequacy or accuracy of this release. This news release may contain forward-looking statements including but not limited
to comments regarding the timing and content of upcoming clinical trials and laboratory results, marketing efforts, funding, etc.
Forward-looking statements address future events and conditions and, therefore, involve inherent risks and uncertainties. Actual
results may differ materially from those currently anticipated in such statements. See the periodic and other reports filed by
Creative Medical Technology Holdings, Inc. with the Securities and Exchange Commission and available on the Commission's website
SOURCE Creative Medical Technology Holdings, Inc.